Lipitor generics poised to pounce as Mylan and Pfizer settle dispute
This article was originally published in Scrip
Executive Summary
Mylan has announced that it has entered into a settlement agreement with Pfizer which will resolve ongoing US litigation related to the firm's blockbuster cholesterol medicine Lipitor (atorvastatin calcium). The terms were not disclosed, but the deal will in all likelihood complement other litigation settlements surrounding the product.